Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S16-S22 , July 2008

24-hour powerful blood pressure-lowering: is there a clinical need?

Based on material presented at a Boehringer Ingelheim-Sponsored Meeting held in Madrid, Spain, May 4–5, 2007.

  • Gordon McInnes, BSc, MD, FRCP

      Affiliations

    • Corresponding Author InformationCorresponding author: Gordon McInnes, BSc, MD, FRCP, Division of Cardiovascular and Medical Sciences, Faculty of Medicine, Western Infirmary, University of Glasgow, Glasgow G11 6NT, United Kingdom. Tel: +44 141 211 2319; fax: +44 141 211 2895.

References 

  1. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet. 1978;1:795–797
  2. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53:96–104
  3. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens. 1987;5:93–98
  4. Palatini P, Penzo M, Racioppa A, Zugno E, Guzzardi G, Anaclerio M, et al. Clinical relevance of night-time blood pressure and of day-time blood pressure variability. Arch Intern Med. 1992;152:1855–1860
  5. Sander D, Klingelhofer J. Diurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosis. Neurology. 1996;47:500–507
  6. Goldstein IB, Bartzokis G, Hance DB, Shapiro D. Relationship between blood pressure and subcortical lesions in healthy elderly people. Stroke. 1998;29:765–772
  7. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19:1981–1989
  8. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11:1133–1137
  9. Pickering TG, James GD. Ambulatory blood pressure and prognosis. J Hypertens Suppl. 1994;12:S29–S33
  10. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation. 2000;102:1536–1541
  11. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473–476
  12. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315–1322
  13. Rocco MB, Barry J, Campbell S, Nabel E, Cook EF, Goldman L, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395–400
  14. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401–1406
  15. Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementy J. Blood pressure surge on rising. J Hypertens. 2004;22:1113–1118
  16. Redon J, Roca-Cusachs A, Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study (Analysis of the control of blood pressure using ambulatory blood pressure monitoring). Blood Press Monit. 2002;7:111–116
  17. Manfredini R, Boari B, Portaluppi F. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation. 2003;108:e72–e73author reply e72–3
  18. Lipicky RJ. Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens Suppl. 1994;12:S17–S18
  19. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker–telmisartan. Blood Press. 2001;10:S27–S32
  20. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685–1691
  21. Parati G, Schumacher H, Mancia G. Evaluating 24-hour antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. (abstract) J Hypertens. 2006;24:S301
  22. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens. 2001;19:703–711
  23. Zhu JR, Bai J, Cai NS, Tang B, Fan WH, Guo JZ, et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl. 2004;145:46–49
  24. Lee YT, Lee CM, Lin CS, Sheu SH, Kuo WK, Tsai CW, et al. A double-blind comparison of the efficacy and tolerability of telmisartan 40–80 mg vs. losartan 50–100 mg in Taiwanese hypertensive patients. Int J Clin Pract Suppl. 2004;145:40–45
  25. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens. 2004;17:347–352
  26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (The Heart Outcomes Prevention Evaluation Study investigators). N Engl J Med. 2000;342:145–153
  27. Williams B, Gosse P, Lowe L, Harper R PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24:193–200
  28. Lacourciere Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19:104–112
  29. Gosse P, Neutel JM, Schumacher H, Lacourciere Y, Williams B, Davidai G. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit. 2007;12:141–147
  30. Van Zwieten PA. The pharmacological properties of lipophilic calcium antagonists. Blood Press Suppl. 1998;2:5–9
  31. Lacourciere Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3:295–302
  32. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9:203–210
  33. Neldam S, Edwards C ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2006;15:151–160
  34. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25:41–46
  35. Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 1993;110:245–252
  36. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645
  37. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens. 2002;16:S13–S16
  38. Wienen W, Entzeroth M, Van Meel JCA, Stangier J, Busch U, Ebner T, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev. 2000;18:127–156
  39. Song JC, White CM. Olmesartan medoxomil (CS-866) (An angiotensin II receptor blocker for treatment of hypertension). Formulary. 2001;36:487–499

 Conflict of interest: none.

PII: S1933-1711(08)00038-7

doi: 10.1016/j.jash.2008.03.004

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S16-S22 , July 2008

Article Tools

* Image Usage & Resolution